Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVX-CoV2373 in Children 6 Months to < 12 Years of Age
NCT05468736Phase 3Completed
- Sponsor
- Novavax
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19) (12 arms), sponsored by Novavax. Primary endpoints: Reactogenicity Incidence and Severity, Incidence and Severity of Medically Attended Adverse Events and 4 more. Started Jul 2022; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05468736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468736.